PMC70 CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN THE FIELD SUGGEST A NEW TAXONOMY  by Lloyd, A et al.
A400 Paris Abstracts
with the framework of Maslow’s hierarchy of needs. In conclusion, Maslow’s hierar-
chy of needs was partially supported by the WHOQOL-BREF.
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OBJECTIVES: The FDA proposed the term ‘patient reported outcomes’ in 2001 which 
grouped concepts such as quality of life (HRQL), satisfaction and preference together 
in terms of their role in regulatory approval. Since then there have been notable 
developments in the ﬁeld, not least the much wider use of stated preference methods 
such as conjoint analysis. METHODS: ISPOR’s Patient Preference Conjoint Analysis 
Working Group convened a team to develop a new taxonomy to characterise the dif-
ferent approaches used to capture patient based data. A thorough review of different 
patient reported methods was undertaken, and based upon discussion and further 
expert review, a taxonomy of methods based was developed. RESULTS: Several 
groups of methods emerged from the review which reﬂected both the underlying data 
that the method produces and also the audience of the data—regulators, payers, policy 
makers and decision makers. Group 1 (Classic PRO) includes different psychometric 
approaches, commonly based upon Likert scale responses. This group includes meas-
ures of HRQL, symptoms and treatment satisfaction. Group 2 (Stated preference) 
describes ordinal methods including conjoint analysis (discrete choice, graded 
pairs)and willingness to pay methods. Group 3 (Cardinal utility) describes cardinal 
methods of capturing health outcomes often used in economic evaluation. Each group 
of methods also has naturally different audiences. CONCLUSIONS: The FDA’s simple 
classiﬁcation of measures as PROs does not reﬂect the diversity and applications of 
patient reported data. The proposed taxonomy we believe reﬂects important differ-
ences in methods and also the different uses of data.
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The quality-adjusted life year (QALY) is a unit of measurement which combines the 
length and quality of life in a way which reduces the number of dimensions which 
must be taken into account in an economic evaluation. In simple cost utility analysis 
(CUA) the problem of allocating scarce resources is reduced to two steps: ranking 
projects by their cost per QALY and deciding upon a threshold cost per QALY above 
which projects will not be funded. Over time there has been increasing dissatisfaction 
with the perceived excessive simplicity of the approach. Partly this has arisen over 
technical questions: which instrument should be used to measure QALYs (the SG, 
TTO, etc.); should the QALY be replaced by the healthy-year equivalent (HYE)—is 
there additive separability between health states; are valid QALY league tables achiev-
able. However there has been also increased questioning of the value basis of the 
QALY. Should ‘utility’ incorporate an individual or social perspective (like the person 
trade-off, PTO); should economics revert to the earlier concept of hedonic, rather than 
preference / utility (i.e., subjective well-being), but, perhaps most fundamentally, can 
QALYs be abstracted from other values relating to the distribution of beneﬁts between 
patients with dissimilar problems, and disregard characteristics of services except 
when they impact upon utility, social well-being (SWB) or some other uni-dimensional 
value. Apart from normative concerns, there are an increasing number of empirical 
studies on societal preferences for health care resource allocation, indicating that the 
QALY maximization hypothesis must be considered as falsiﬁed. The broad range of 
documented ‘contextual’ variables implies that a uniform ‘social value’ of a QALY 
does not exist, and suggests that projects designed to determine the dollar value of a 
QALY will either fail or mislead policy.
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OBJECTIVES: Patient-Reported Outcomes (PRO) are routinely used to measure 
disease severity, perceived treatment impact, or patient attitude toward treatment. 
However, adherence can only partially be explained by clinical and these PRO varia-
bles alone. Our objective was to develop a generic Acceptability measure assessing 
how patients balance out between advantages and disadvantages of long-term treat-
ments. It could be used in future adherence studies. METHODS: A literature review 
was conducted in biomedical databases using keywords related to acceptability, per-
ceptions, motivations and barriers linked to treatment, allowing the initial conceptual 
model of Acceptability to be developed. Exploratory interviews were performed with 
5 pharmacists and 18 patients. They were recorded, transcribed word-for-word and 
systematically analysed in order to complete the initial conceptual model. Items of the 
ACCEPT© questionnaire were generated in French for each concept identiﬁed, using 
patients’ words. The resulting test version was tested for relevance and comprehension 
with 5 patients, and revised accordingly; the new version was tested on a second set 
of 5 patients and revised to create the pilot version of the ACCEPT© questionnaire. 
RESULTS: In the test version, items generated for each concept identiﬁed were organ-
ised into 6 sections: drug characteristics, duration, constraints, side-effects, efﬁcacy 
and global acceptability of treatment. Except a few items that were modiﬁed or deleted 
following patients’ suggestions and some minor modiﬁcations in the answer choices, 
the questionnaire was globally very well accepted, easy to complete, and considered 
relevant and appropriate by patients. The pilot version of the ACCEPT© questionnaire 
contains 32 questions divided into the same 6 sections as the test version. CONCLU-
SIONS: The comprehension tests conﬁrmed the existence of the previously hypothe-
sised concept of treatment Acceptability. The ACCEPT© questionnaire will allow the 
Acceptability of a great variety of long-term treatments to be assessed, while being a 
speciﬁc instrument making sense to each individual.
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OBJECTIVES: The Institute for Quality and Efﬁciency in Health Care (IQWiG) 
assesses the beneﬁt and costs of drugs by considering their affordability and reasona-
bleness from the insurants’ viewpoint. IQWiG forwards its assessments to the German 
Federal Joint Committee (G-BA) in the form of recommendations, which may be used 
in establishing ceiling prices for drug innovations. Within the framework of its 
methods proposal, IQWiG does not negate an intra-indication-related application of 
QALYs for cost-beneﬁt assessments. However, depending on the methods applied and 
the target populations surveyed, different results can be generated for evaluating states 
of health. No international standard exists for a preferred method. METHODS: After 
performing a systematic literature search to identify studies in which various methods 
for documenting beneﬁt were applied and different target populations were investi-
gated, selected studies are presented, whose incremental cost-utility-ratios have an 
(extremely) wide scatter related to the documenting. Depending on the documenting 
method, indication-dependent trends are investigated for effect size and direction of 
QALYs. RESULTS: The studies identiﬁed show that the variation in methods for 
documenting QALYs even within the same intervention trial considerably reduces its 
comparability. It is also not easily possible for decision-makers to make a decision 
based on these results. The documenting methods used clearly create different con-
structs that apparently display different levels of responsiveness in the same indication 
(e.g. rheumatoid arthritis, sleep apnoea, macular degeneration, oral anticoagulation). 
In the inter-indication comparison, a clear trend could not be determined for the effect 
size in the results in relation to the documenting methods used. CONCLUSIONS: If 
the legal conditions are satisﬁed and a consistent decision using cost-utility analyses 
in one indication area is possible, the documenting method for utilities must be 
standardised. This could be directed indication-speciﬁc towards an optimum corre-
spondence with the responsiveness of validated, disease-speciﬁc quality of life docu-
menting instruments.
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Conventional health economic tools are not adapted to the very speciﬁc problems of 
metastatic cancer treatment. The objective of this study was to analyze the methodo-
logical tools used in published economic evaluations for metastatic breast cancer 
(empirical studies) and for all metastatic cancer treatments (methodological studies). 
Results of a systematic literature search (Medline, Embase, Cochrane Library, Pascal, 
HTA databases) since 1990 were completed by expert interviews (oncologists, health 
economists, decision-makers). 535 abstracts were screened and 80 selected, excluding: 
clinical trials with no economic analysis, alternative treatments to chemotherapy, early 
stages of cancer, any metastatic cancer with no speciﬁc and/or original methodology 
and/or endpoints. According to a pharmacoeconomic quality checklist, 37 were ana-
lyzed. The review showed a majority of studies in breast cancer with low level of evi-
dence and only two prospective studies. More than half of the studies were cost-utility 
analyses. Endpoints combine quality of life and other indicators: QALY (Quality-
Adjusted Life Years), Q-TWiST (Quality-Adjusted Time Without Symtoms and Toxic-
ity), QAPFYs (Quality-Adjusted Progression-Free life Years), QADs (Quality-Adjusted 
Days of life). We did not ﬁnd any speciﬁc criterion to the metastatic state. Experts 
recommend the use of multi-dimension criteria comprising direct and indirect costs, 
efﬁcacy and quality of life data integrating patient preferences; thresholds of resource 
allowance should be deﬁned according to treatment strategies and population sub-
groups (performance status, age, illness severity). This study underlines the need to 
develop tools for poor prognosis diseases and raises the issue of the integration of 
economic rationality in the health care decisions in France. Although some countries 
have chosen arbitrations (QALY, Efﬁciency Frontier per pathology), France has not 
yet chosen a validated method for resources allocation.
